Pluristem Therapeutics, Inc.PSTI was a big mover last session, as its shares rose almost 12% on the day. The upside was driven by the release of positive data from studies of the company's PLX-PAD cells in the treatment of Duchenne muscular dystrophy. This also move led to far more shares changing hands than in a normal session. Yesterday's rally reverses the downtrend for the company, as the stock is now down almost 13% in the past one-month time frame.
Over the last 30 days, the company did not witness any estimate revision and the Zacks Consensus Estimate also remained unchanged. Yesterday's price action is encouraging though, so make sure to keep a close watch on this firm in the near future.
Pluristem Therapeutics has a Zacks Rank #2 (Buy) while its Earnings ESP is 0.00%.
PLURISTEM THERA Price
Another favorably ranked stock in the biomedical space is ANI Pharmaceuticals, Inc. ANIP , sporting a Zacks Rank #1 (Strong Buy).